GSK Bolsters Cardiovascular Portfolio With Acquisition Of Reliant
Executive Summary
GlaxoSmithKline's acquisition of Reliant for $1.65 billion will give the U.K. drug maker access to a growing cardiovascular drug in the U.S., Lovaza. The drug will complement GSK's existing CV portfolio, including the hypertension drug Coreg CR